08th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160051546 | CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA - Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m | 2016-02-25 |
20160051547 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2016-02-25 |
20160051548 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders - The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety. | 2016-02-25 |
20160051549 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 - The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. | 2016-02-25 |
20160051550 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE - The invention provides A combination of, a) a compound of Formula Ia: | 2016-02-25 |
20160051551 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS - A pharmaceutical formulation comprising the compound of formula | 2016-02-25 |
20160051552 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 2016-02-25 |
20160051553 | Molecular and Herbal Combinations with Methotrexate for Treating Diseases and Inflammatory Ailments - A treatment regimen for psoriasis, eczema or other skin ailment, inflammation, autoimmune disease, leukemia, melanoma or other cancer includes administering to a patient a methotrexate regimen along with periodic doses of an herbal combination including Sheng Di Huang, Da Huang or Jin Yin Hua or combinations thereof. | 2016-02-25 |
20160051554 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS - Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient. | 2016-02-25 |
20160051555 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds: | 2016-02-25 |
20160051556 | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression - The present invention relates to an isolated EGF receptor agonist for use in the treatment of chronic liver diseases associated with a low hepcidin expression such as alcoholic liver disease, chronic hepatitis C, or genetic hemochromatosis. | 2016-02-25 |
20160051557 | METHODS OF TREATING PROLIFERATIVE DISEASES - Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided. | 2016-02-25 |
20160051558 | PHARMACEUTICAL COMPOSITION FOR INHIBITING IMMUNE RESPONSE THROUGH INDUCING DIFFERENTIATION INTO REGULATOR T CELLS AND PROMOTING PROLIFERATION OF REGULATOR T CELLS - The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells. | 2016-02-25 |
20160051559 | 3, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE - Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: | 2016-02-25 |
20160051560 | TREATMENTS INVOLVING ESLICARBAZEPINE OR ESLICARBAZEPINE ACETATE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient. | 2016-02-25 |
20160051561 | High Dosage Strength Tablets of Rucaparib - A tablet including high dosage of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one camsylate salt has been disclosed. | 2016-02-25 |
20160051562 | METHODS AND COMPOSITIONS FOR REDUCING BODY FAT AND ADIPOCYTES - Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): | 2016-02-25 |
20160051563 | Oral Transmucosal Pharmaceutical Compositions including Testosterone and an Aromatase Inhibitor - Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and AI. Oral transmucosal compositions will deliver testosterone and AI directly into the patient's bloodstream, and provide high bioavailability of testosterone and AI; therefore, the required doses are lower. | 2016-02-25 |
20160051564 | Oral Transmucosal Pharmaceutical Compositions Including Testosterone and a C-SERM - Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with a clomiphene-like selective estrogen receptor modulator (C-SERM) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and C-SERM. Oral transmucosal compositions will deliver testosterone and C-SERM directly into the patient's bloodstream, and provide high bioavailability of testosterone and C-SERM; therefore, the required doses are lower. | 2016-02-25 |
20160051565 | Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor - Formulations for transdermal pharmaceutical compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transdermal permeation enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Transdermal pharmaceutical compositions include liquid dosage forms, such as, for example solutions, liquid sprays, lotions, and the like. Additionally, transdermal pharmaceutical compositions include semi-solid dosage forms, such as, for example emulsions, creams, gels, pastes, ointments, and the like. Transdermal pharmaceutical compositions will deliver testosterone and AI through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of testosterone and AI. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol. | 2016-02-25 |
20160051566 | Enzymatic Process for Obtaining 17 Alpha-Monoesters of Cortexolone and/or Its 9,11-Dehydroderivatives - The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate. | 2016-02-25 |
20160051567 | PREVENTION AND TREATMENT OF KIDNEY DAMAGE - A method of treating or preventing kidney injury includes administering to a patient an effective amount of bile acid, a salt thereof, an analog thereof, or a combination thereof. Methods of preventing or retarding, reversing or abolishing the onset of kidney injuries are discussed. This is achieved through the administration of a bile acid, a salt of the bile acid, an analog of the bile acid or any combinations of these compounds. The bile acid abolishes or interferes or down-regulates metabolic pathways leading to the onset of kidney injury. The bile acid also activates metabolic pathways leading to the slowing or reversing or complete abolishment of the progression of acute kidney injury. | 2016-02-25 |
20160051568 | CYCLODEXTRIN AND BUDESONIDE DERIVATIVE COMPOSITIONS AND METHODS - The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations. | 2016-02-25 |
20160051569 | Methods for Inhibiting the Development, Formation and/or Maturation of Bacterial and Fungal Biofilms - The present disclosure describes compositions and methods for inhibiting the development, formation and/or maturation of bacterial and fungal biofilms. The biofilm inhibiting compositions include non-steroidal anti-inflammatory drugs (NSAIDs) as APIs, and ethoxylated oil as a solubilizing agent. The ethoxylated oils employed within the biofilm inhibiting compositions includes between 9 and 24 ethoxylations/molecules. The NSAIDs agents within the biofilm inhibiting compositions inhibit the syntheses of prostaglandins by blocking the cyclooxygenase (COX) enzyme system due to the analgesic, anti-inflammatory, and antipyretic properties of the NSAIDs. The biofilm inhibiting compositions inhibit the cyclooxygenase isoenzymes required for prostaglandin formation, thereby preventing the colonization of fungi or bacteria as well as the formation of biofilms. | 2016-02-25 |
20160051570 | TREATMENT OF RHEUMATOID ARTHRITIS - A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and treating chronic inflammation. A method of reducing and/or eliminating symptoms of chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and reducing and/or eliminating the individual's symptoms of chronic inflammation. | 2016-02-25 |
20160051571 | TRIPTOLIDE PRODRUGS - The invention provides compounds of formula I: | 2016-02-25 |
20160051572 | TRAUMA THERAPY - The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic. | 2016-02-25 |
20160051573 | STRUCTURE AND USE OF 5' PHOSPHATE OLIGONUCLEOTIDES - Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1β production. Bacterial RNA also induces type I IFN production. 5′ phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5′ triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1β production, in a target cell-specific manner. | 2016-02-25 |
20160051574 | COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT - This invention relates to compositions for reducing the absorption or bioavailability of lipids in the gastrointestinal tract, and to methods for the preparation and use of these compositions. The compositions comprise a source of dietary fibre together with a cyclodextrin. The compositions of the invention are suitable for use in the prevention and treatment of obesity or hyperlipidaemia. | 2016-02-25 |
20160051575 | HEPARIN-BASED COMPOSITIONS AND METHODS FOR THE INHIBITION OF METASTASIS - The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis. | 2016-02-25 |
20160051576 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 2016-02-25 |
20160051577 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H | 2016-02-25 |
20160051578 | COMPOSITION FOR THE TREATMENT OF DISEASE - A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis. | 2016-02-25 |
20160051579 | NITRIC OXIDE TREATMENT OF BOVINE RESPIRATORY DISEASE COMPLEX AND OTHER RESPIRATORY CONDITIONS - Methods, devices, and systems for treating a respiratory condition using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the respiratory condition may be bovine respiratory disease complex (BRDc). | 2016-02-25 |
20160051580 | SUPPLY OF XENON OR ARGON GAS TO A DONOR PRIOR TO TAKING A SAMPLE OF BIOLOGICAL MATERIAL - The invention relates to a gaseous composition containing an active gaseous compound selected from the group made up of Xe and Ar to be used for preventing or minimising an ischaemia-reperfusion lesion of a biological material in a donor patient, while and/or immediately after taking a sample of said biological material from said donor patient, said gaseous composition being administered to the donor patient prior to taking the sample of biological material from said donor patient. | 2016-02-25 |
20160051581 | DELIVERY OF ARGON TO A RECIPIENT OF BIOLOGICAL MATERIAL - The invention relates to a gaseous composition containing argon as an active gaseous compound for use to prevent or minimize an ischaemia-reperfusion lesion of a biological material in a recipient individual, during and/or subsequent to the transplantation of said biological material in said recipient individual, wherein said gaseous composition is administered to the recipient individual prior to, during and/or subsequent to the surgical operation aimed at grafting the biological material in said recipient individual. | 2016-02-25 |
20160051582 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CHRONIC PAIN - A pharmaceutical composition for treatment of chronic pain includes lidocaine, glucose, sodium chloride and sodium bicarbonate. The pharmaceutical composition could be applied for treatment of chronic pains in local position such as soft tissue, muscle tendon, synovial bursa. | 2016-02-25 |
20160051583 | METHOD AND COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS - The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that seawater has more magnesium in it than in naturally occurring seawater. The treatment of acne and the like can be improved with the product of the present invention. | 2016-02-25 |
20160051584 | MICROPOROUS ZIRCONIUM SILICATE AND DIURETICS FOR THE REDUCTION OF POTASSIUM AND TREATMENT OF CHRONIC KIDNEY AND/OR CHRONIC HEART DISEASE - The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease. | 2016-02-25 |
20160051585 | COMBINED PROTEIN SUPPLEMENTS - Protein supplements that include proteins from animal products, such as whey and eggs, are disclosed. Such a protein supplement may also include one or more immune modulators, such as transfer factor and/or nanofraction immune modulators. | 2016-02-25 |
20160051586 | METHODS OF GROWING AND PREPARING STEM CELLS AND METHODS OF USING THE SAME - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor, utilizing allogeneic, autologous or xenogeneic cells, mixing the cells with platelet rich plasma that is autologous, allogeneic or xenogeneic to the subject, and site specific delivery of between about three and ten million activated stem cells per kilogram of the subject receiving the treatment. | 2016-02-25 |
20160051587 | INTERNAL MEDICINE DOSING OF STEM CELLS - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise site specific delivery of between five and fifteen million stem cells at the site and systemic administration of between about three and ten million cells per kilogram of the subject receiving the treatment. | 2016-02-25 |
20160051588 | METHOD OF USING STEM CELLS AND NANOWHISKERS - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor and/or through the introduction of nanofibers to cells in suspension, utilizing allogeneic cells that are mixed with platelet rich plasma that is autologous to the subject, and site specific delivery of between 5 and 15 million stem cells at the site or of about 3-10 million stem cells per kilogram of the subject receiving the treatment. | 2016-02-25 |
20160051589 | MULTIPOTENT POSTNATAL STEM CELLS FROM HUMAN PERIODONTAL LIGAMENT AND USES THEREOF - The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation. | 2016-02-25 |
20160051590 | COMPOSITIONS AND METHODS FOR TREATMENT OF VESSEL DISEASE - The present disclosure relates to compositions and methods for the treatment of blood vessel disease. More specifically, the compositions and methods of the present disclosure make use of a population of stromal vascular fraction cells. In some embodiments, the population of stromal vascular fraction cells comprises at least one macrophage. | 2016-02-25 |
20160051591 | METHOD FOR THE SEPARATION OF FUNCTIONAL INGREDIENTS IN PLACENTA - The present invention provides a method for the separation of placenta functional ingredients. By using the supercritical fluid technology, the placenta powder is placed inside an extraction tank, under the predetermined pressure and temperature; the supercritical CO | 2016-02-25 |
20160051592 | Methods of treating diseases with human trophoblast stem cells - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies. | 2016-02-25 |
20160051593 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF - The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies. | 2016-02-25 |
20160051594 | Therapeutic Compositions and Uses Thereof - The invention provides pharmaceutical compositions, including anti-gastrointestinal cancer compositions, containing propolis and cyclodextrin. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and in the resenitisation of gastrointestinal cancers to therapy, are also provided. | 2016-02-25 |
20160051595 | EXTERNAL-USE MEDICAMENT FOR CLEANING AND CARE OF THE OVARIES, VAGINA AND VULVA - An external-use agent for cleaning and caring ovaries, vagina and vulva, which is produced by medical raw materials consisting of propolis extract, zedoary oil, and mint leaf filtrate is provided. On the basis of different properties of each natural Chinese herbal material, using supercritical CO | 2016-02-25 |
20160051596 | NOVEL ACETOBACTER AND GLUCONACETOBACTER STRAINS AND THEIR METABOLITES FOR USE IN INHIBITING XANTHINE OXIDASE - A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing | 2016-02-25 |
20160051597 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS - The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a human. These methods include administering intratumorally to the human a unit dose of | 2016-02-25 |
20160051598 | NOVEL ACETOBACTER AND GLUCONACETOBACTER STRAINS AND THEIR METABOLITES FOR USE IN INHIBITING XANTHINE OXIDASE - A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing | 2016-02-25 |
20160051599 | COMPOSITIONS AND METHODS FOR IMPROVING THE HEALTH OF AQUATIC ANIMALS - The present invention relates to compositions and methods for increasing the health of aquatic animals comprising one or more selected bacterial strains. | 2016-02-25 |
20160051600 | GELATINOUS MIXTURE OF PROBIOTICS AND PREBIOTICS WITH SYNERGIC SYMBIOTIC ACTION FOR TREATING CHRONIC RENAL DISEASE - The invention relates to the fields of application of health, biotechnology and nutrition, the aim of the invention being to provide a gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease, the characteristics and components thereof reducing the concentration of uremic toxins, improving the renal function of the patient with an increase in urea, creatinine, uric acid, p-cresols or indoles in the blood. The gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease is easier to administrate orally as it does not require the consumption of liquids for the administration thereof, reducing liquid retention. Another advantage of the present invention is the fact that it refers to live and active bacteria. The present invention is also used a primary source of food with known prebiotic effects, an element which is not considered in other inventions; it is not in a pharmaceutical form. The probiotic bacteria are found “live and active” and in “synergic action” with the prebiotic fibres of plant origin such as “blue agave fructans (blue agave inulin)”. | 2016-02-25 |
20160051601 | COSMETIC AND PHARAMCEUTICAL APPLICATIONS OF LACTOBACILLUS PENTOSUS - The invention concerns a cosmetic or dermatological composition for topical use comprising, as an active ingredient, the combination of a culture supernatant and of a cell lysate, from a | 2016-02-25 |
20160051602 | NOVEL STRAIN OF LACTOBACILLUS RHAMNOSUS AND ITS METABOLITES FOR USE IN INHIBITING XANTHINE OXIDASE AND TREATING GOUT - A method for inhibiting xanthine oxidase and for reducing uric acid levels using a composition obtained by culturing | 2016-02-25 |
20160051603 | Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof - A recombinant vector comprises simian adenovirus 28, simian adenovirus 27, simian adenovirus 32, simian adenovirus 33, and/or simian adenovirus 35 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-28, -27, -32, -33, or -35 genes is also disclosed. Methods of using the vectors and cell lines are provided. | 2016-02-25 |
20160051604 | SEAWEED EXTRACTS, UNSATURATED ALDEHYDES, AND METHODS OF TREATMENT - The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)-mediated diseases and diseases mediated through the activation of the Nrf2-ARE (antioxidant response element) pathway, including proliferative diseases and disorders, Alzheimer's disease, stroke, and certain diseases and disorders of aging and associated with aging and exposure, by use of the extracts, compounds, and compositions thereof. | 2016-02-25 |
20160051605 | COMPOSITION FOR BRAIN ACTIVATION, COMPRISING GINSENG FRUIT EXTRACT - Provided in the present specification is a composition for brain activation, comprising ginseng fruit extract as an active ingredient. The composition according to the present specification allows an increase in blood flow in the brain and thus has an effect of ameliorating chronic fatigue syndrome. In addition, the composition according to the present specification activates the brain, and as a result, strengthens connectivity strength between the frontal lobe and the occipital lobe and thus has an effect of improving problem-solving accuracy and reducing solving time in the area of cognitive ability. Therefore, the composition according to the present specification can be used as a pharmaceutical composition or a food composition for patients suffering from chronic fatigue syndrome. | 2016-02-25 |
20160051606 | COMPOSITION FOR LIFE EXTENSION CONTAINING GINSENG FRUIT EXTRACT - The present invention relates to a composition for life extension and particularly to a composition for life extension containing a | 2016-02-25 |
20160051607 | Topical Pharmaceutical Bases for Preventing Viral Diseases - The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases. | 2016-02-25 |
20160051608 | ANTI-CANCER EXTRACT AND COMPOUNDS - The present invention relates to a new approach for treating a cancer or fibrosis, such as hepatocellular carcinoma, or liver fibrosis using an extract from a plant of | 2016-02-25 |
20160051609 | Topical Pharmaceutical Bases for Treating Inflammatory Disorders - The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders. | 2016-02-25 |
20160051610 | Topical Pharmaceutical Bases for Treating Skin Conditions - The present disclosure refers to topical pharmaceutical bases that possess scar healing properties. Further, these topical pharmaceutical bases are proposed for treating skin conditions, such as, for example keloids, hypertrophic scars, wounds, and burns, among others. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective scar and wound treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve healing effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating skin conditions. | 2016-02-25 |
20160051611 | Topical Pharmaceutical Bases for Wound and Scar Treatment - The present disclosure refers to topical pharmaceutical bases that include a synergistic combination of pracaxi oil, andiroba oil, copaiba balsam, and ucuuba butter. Further, these topical pharmaceutical bases are proposed for treating skin conditions in mammals, such as, for example wounds and scars. The topical pharmaceutical bases provide healing, moisturizing, anti-inflammatory, antibacterial, and antifungal effect. Additionally, the topical pharmaceutical bases enable an effective administration of specific active pharmaceutical ingredients (APIs), thereby improving treatment outcomes. Topical pharmaceutical compositions including the topical pharmaceutical bases increase the residence time of APIs within a wound or scar, thereby improving the penetration of APIs into the affected area. Also, the topical pharmaceutical bases provide relatively uniform distribution of the APIs within the topical pharmaceutical compositions. Further, the topical pharmaceutical compositions release APIs slowly, thereby enhancing treatment effectiveness. | 2016-02-25 |
20160051612 | THE COMPOSITION COMPRISING A PURIFIED EXTRACT ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING ABUNDANT AMOUNT OF ACTIVE INGREDIENT OR THE COMPOUNDS ISOLATED THEREFROM, AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THE USE THEREOF - A composition comprising a purified extract isolated from | 2016-02-25 |
20160051613 | WHOLE GREEN COFFEE BEAN PRODUCTS AND METHODS OF PRODUCTION AND USE FOR FOCUS AND CONCENTRATION - Disclosed are novel processing methods for green coffee beans that result in novel green coffee bean products, including products that incorporate whole green coffee beans. Methods include selecting whole coffee beans in their fresh green unroasted state with naturally-occurring levels of phytonutrients, sterilizing and drying them, applying iterative grinding processes and stabilization techniques, all while avoiding high temperatures. Whole green coffee bean products created and defined by these methods have unexpectedly been found to increase focus and concentration in users, and are believed useful in the treatment of attention and concentration deficits and related disorders, such as attention deficit (AD), attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and various related and/or comorbid disorders. | 2016-02-25 |
20160051614 | PLANT BASED FORMULATION FOR THE PREVENTION AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME (IBS) - The invention relates to a plant based formulation for the prevention and management of Irritable Bowel Syndrome (IBS) comprising of effective amount of a hydro-alcoholic extract of | 2016-02-25 |
20160051615 | PLANT BASED FORMULATION FOR THE PREVENTION AND MANAGEMENT OF METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE MORTALITY RISK - The invention relates to a plant based formulation for the prevention and management of Metabolic Syndrome and Cardiovascular disease mortality risk comprising an effective amount of a hydro-alcoholic extract of | 2016-02-25 |
20160051616 | Joint pain treatment method of use - The invention is directed to a homeopathic joint pain treatment composition. The composition comprises an animal fat such as lard mixed with onions and rosemary herb. The onions and rosemary herb may be finely chopped or pureed to give the composition a homogeneous appearance, and provide for the maximum release of their essential oils. The composition is applied to affected areas, such as joints, topically with massage. | 2016-02-25 |
20160051617 | PLANT BASED FORMULATION FOR THE PREVENTION AND MANAGEMENT OF METABOLIC SYNDROME BY ITS ADIPONECTIN ENHANCING PROPERTY - The invention relates to a plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property comprising of an effective amount of hydro-methanolic extract of | 2016-02-25 |
20160051618 | ACTIVE SUBSTANCE FOR TREATING SARCOPENIA - The present invention relates to collagen hydrolysate as an active substance for treating sarcopenia, as an active substance against the degenerative loss of muscle mass and for improving muscle power, as an active substance for reducing the age-related loss of muscle mass, and as an active substance for stimulating the conversion of body fat mass to muscle mass. The invention further relates to a method for treating sarcopenia, comprising the repeated oral administration of collagen hydrolysate to a patient. | 2016-02-25 |
20160051619 | TREATMENT OF PROTEIN DEGRADATION DISORDERS - The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds. | 2016-02-25 |
20160051620 | Methods for regulating transcription of multiple genes and expression of multiple targets - This invention discloses methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide, wherein the polypeptide comprising the amino acid sequence of SEQ ID No.1 and/or homology thereof. The present polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes. | 2016-02-25 |
20160051621 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY - The present invention refers to a peptidic or non-peptidic angiotensin(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome. | 2016-02-25 |
20160051622 | Accelerated healing of eye injuries by angiotensin peptides - Disclosed herein are methods for treating eye injuries by administering one or more angiotensin peptides to a subject with an eye injury. | 2016-02-25 |
20160051623 | ANTI-ANGIOGENIC PEPTIDES AND USES THEREOF - Provided are peptide sequences derived from prostate serum antigen (PSA). The peptides are provided in cyclic and linear form. Methods for using the peptides for inhibition of angiogenesis, such as angiogenesis in a tumor, are provided. | 2016-02-25 |
20160051624 | ANTIBACTERIAL COMPOSITIONS FOR DRUG ADMINISTRATION - Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi. | 2016-02-25 |
20160051625 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 2016-02-25 |
20160051626 | COMPOSITIONS COMPRISING COMPLEXES OF PROANTHOCYANIDINS WITH VEGETABLE PROTEINS - Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue. | 2016-02-25 |
20160051627 | LONG LASTING DRUG FORMULATIONS - The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha. | 2016-02-25 |
20160051628 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS - The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 2016-02-25 |
20160051629 | INHIBITION OF RIP KINASES FOR TREATING LYSOSOMAL STORAGE DISEASES - The present invention provides compositions and methods for treating lysosomal storage disease characterized by elevation of RIP kinase in a subject in need thereof using at least one RIP kinase inhibitor. | 2016-02-25 |
20160051630 | POSTPRANDIAL GASTROKINETIC AGENT - To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake. | 2016-02-25 |
20160051631 | DOSAGE REGIMEN FOR THERAPEUTIC METHOD - Disclosed herein is the use of an active agent comprising a peptide derived from atrial natriuretic peptide (ANP) prohormone or a mimetic thereof in the manufacture of a medicament for treating a disease in a subject. The medicament is administered subcutaneously in a multimodal dosage regime comprising at least an initial dosage stage and at least one maintenance dosage stage. The initial dosage stage comprises infusing the active agent at an initial dosage rate for an initial period to achieve a target steady state blood plasma concentration of the active agent or metabolite thereof. The maintenance dosage stage(s) comprise(s) adjusting the dosage rate to a maintenance dosage rate for a maintenance period to substantially maintain said target steady state blood plasma concentration of the active agent or metabolite thereof. | 2016-02-25 |
20160051632 | Chimeric Natriuretic Peptide Compositions and Methods of Preparation - Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described. | 2016-02-25 |
20160051633 | METHODS OF TREATING HEMOPHILIA IN PATIENTS HAVING DEVELOPED INHIBITORY ANTIBODIES - This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. | 2016-02-25 |
20160051634 | SUPPRESSION OF CANCER METASTASIS - Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. | 2016-02-25 |
20160051635 | BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE - The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood. | 2016-02-25 |
20160051636 | Animal Feed Enzymes - The present invention relates to methods of controlling the growth of microorganisms in animals and animal feed. In particular, the present invention relates to a method of controlling the growth of microorganisms in animals with an antimicrobial composition, the treatment of animal feed with an antimicrobial additive and antimicrobial compositions. | 2016-02-25 |
20160051637 | LIPOPROTEIN LIPASE FOR TREATMENT OF HYPERTRIGLYCERIDEMIC-RELATED CONDITIONS INCLUDING ACUTE PANCREATITIS - A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome. | 2016-02-25 |
20160051638 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS - The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided. | 2016-02-25 |
20160051639 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF - The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies. | 2016-02-25 |
20160051640 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 2016-02-25 |
20160051641 | STABILIZED THROMBIN - The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide. | 2016-02-25 |
20160051642 | TREATMENT OF PEYRONIE'S DISEASE - The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization, and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios. | 2016-02-25 |
20160051643 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin. | 2016-02-25 |
20160051644 | Botulinum Chimera Compositions for Axonal Regenerative Therapy During Spinal Cord Injury - The present invention relates to the isolation of polypeptides derived from the | 2016-02-25 |
20160051645 | Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds - Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases. | 2016-02-25 |